Delving Into Design & Engineering of FGFR2b ADC to Reduce Ocular Toxicity & Enhance Anti-Tumor Efficacy Compared to mAb Therapy
- Laying out the room for improvement with targeting FGFR2b by mAb by optimizing safety and efficacy profile
- Exploring design rationale for FGFR2b ADC with reduced signal blockade and string bystander killing activity
- Evaluating the preclinical profile of FGFR2b ADC with absence of ocular toxicity in preclinical species and strong efficacy in CDX and PDX models with heterogenous antigen expression